BRPI0817753A8 - Terapia gênica de cartilagem articular com vetor recombinante codificando bmp-7 - Google Patents

Terapia gênica de cartilagem articular com vetor recombinante codificando bmp-7

Info

Publication number
BRPI0817753A8
BRPI0817753A8 BRPI0817753A BRPI0817753A BRPI0817753A8 BR PI0817753 A8 BRPI0817753 A8 BR PI0817753A8 BR PI0817753 A BRPI0817753 A BR PI0817753A BR PI0817753 A BRPI0817753 A BR PI0817753A BR PI0817753 A8 BRPI0817753 A8 BR PI0817753A8
Authority
BR
Brazil
Prior art keywords
gene therapy
vector encoding
articular cartilage
recombinant vector
encoding bmp
Prior art date
Application number
BRPI0817753A
Other languages
English (en)
Portuguese (pt)
Inventor
Bernard Fischer Laurent
Original Assignee
Merial Ltd
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Ltd, Merial Inc filed Critical Merial Ltd
Publication of BRPI0817753A2 publication Critical patent/BRPI0817753A2/pt
Publication of BRPI0817753A8 publication Critical patent/BRPI0817753A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/10—Animals modified by protein administration, for non-therapeutic purpose
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/102—Caprine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
BRPI0817753A 2007-10-05 2008-10-07 Terapia gênica de cartilagem articular com vetor recombinante codificando bmp-7 BRPI0817753A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/867,919 US7846428B2 (en) 2007-10-05 2007-10-05 Articular cartilage gene therapy with recombinant vector encoding BMP-7
PCT/US2008/079090 WO2009046464A1 (en) 2007-10-05 2008-10-07 Articular cartilage gene therapy with recombinant vector encoding bmp-7

Publications (2)

Publication Number Publication Date
BRPI0817753A2 BRPI0817753A2 (pt) 2015-03-24
BRPI0817753A8 true BRPI0817753A8 (pt) 2017-09-26

Family

ID=40276182

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0817753A BRPI0817753A8 (pt) 2007-10-05 2008-10-07 Terapia gênica de cartilagem articular com vetor recombinante codificando bmp-7

Country Status (7)

Country Link
US (1) US7846428B2 (enExample)
EP (1) EP2205743B1 (enExample)
JP (1) JP2012505151A (enExample)
CN (1) CN102027114A (enExample)
BR (1) BRPI0817753A8 (enExample)
CA (1) CA2701215C (enExample)
WO (1) WO2009046464A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011084145A2 (en) * 2009-12-21 2011-07-14 Pharmathene, Inc. Recombinant butyrylcholinesterases and truncates thereof
RU2516951C1 (ru) * 2013-03-01 2014-05-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарёва" Способ профилактики посттравматического артроза коленного сустава
HRP20181913T1 (hr) 2013-07-18 2019-01-11 Xalud Therapeutics, Inc. Sastav za liječenje upale bolesti zglobova
WO2015035395A1 (en) * 2013-09-09 2015-03-12 Figene, Llc Gene therapy for the regeneration of chondrocytes or cartilage type cells
RU2771490C2 (ru) 2016-01-13 2022-05-05 Мериал, Инк. Рекомбинантные aav векторы, экспрессирующие остеопротективные гены, включая has2 и лубрицин, пригодные при лечении остеоартрита и сходных заболеваний суставов у млекопитающих
US10617739B2 (en) * 2016-04-13 2020-04-14 Universiteit Maastricht Method for the treatment or prevention of osteoarthritis
AU2018258100B2 (en) * 2017-04-27 2022-04-14 Eli Lilly And Company Variants of human BMP7 protein
US11246836B2 (en) * 2018-05-17 2022-02-15 Bluelight Pharmatech Co., Ltd. Intramuscular depot of decoquinate compositions and method of prophylaxis and treatment thereof
CN112168793A (zh) * 2020-10-26 2021-01-05 辰欣药业股份有限公司 一种盐酸氨溴索口腔崩解片及其制备方法
US20240316219A1 (en) * 2021-05-03 2024-09-26 North Carolina State University Compositions and methods related to the treatment of ocular diseases in equines

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266683A (en) * 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US6159464A (en) * 1990-12-20 2000-12-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education Viral vectors to inhibit leukocyte infiltration or cartilage degradation of joints
WO2002083080A2 (en) * 2001-04-17 2002-10-24 Genetix Pharmaceuticals, Inc. Method of treating arthritis using lentiviral vectors in gene therapy
US20040167088A1 (en) * 2003-02-25 2004-08-26 Genvec, Inc. Method of using adenoviral vectors with increased persistence in vivo
WO2004083434A1 (en) * 2003-03-17 2004-09-30 The University Of Hong Kong A combined adeno-associated virus and adenovirus cocktail gene delivery system for high effiency gene expression without eliciting immune response in immuno-competent subjects
WO2005007098A2 (en) * 2003-07-08 2005-01-27 New York University Nucleic acid therapy to enhance cartilage repair
EP1660663A4 (en) * 2003-08-12 2007-07-11 Brigham & Womens Hospital METHOD AND COMPOSITIONS FOR TISSUE REPAIR
EP1951751B1 (en) 2005-11-14 2017-11-01 Merial, Inc. Gene therapy for renal failure
EP1978994B1 (en) * 2005-12-22 2012-02-01 Janssen Biotech, Inc. Bmp-7 variant compositions, methods and uses

Also Published As

Publication number Publication date
CA2701215A1 (en) 2009-04-09
CN102027114A (zh) 2011-04-20
CA2701215C (en) 2016-05-17
US7846428B2 (en) 2010-12-07
BRPI0817753A2 (pt) 2015-03-24
EP2205743A1 (en) 2010-07-14
EP2205743B1 (en) 2017-07-19
WO2009046464A8 (en) 2012-04-26
WO2009046464A1 (en) 2009-04-09
JP2012505151A (ja) 2012-03-01
US20090093427A1 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
BRPI0817753A8 (pt) Terapia gênica de cartilagem articular com vetor recombinante codificando bmp-7
BR112017018728A2 (pt) sistema de vetor para expressar a sequência de codificação de um gene de interesse em uma célula, célula hospedeira, composição farmacêutica, método para tratar e/ou prevenir uma patologia ou doença, uso de uma sequência de nucleotídeo de um sinal de degradação em um sistema de vetor e método para diminuir a expressão de uma proteína na forma truncada
CY1123760T1 (el) Ανασυνδυασμενοι φορεις aav που εκφραζουν οστεοπροστατευτικα γονιδια, που περιλαμβανουν has2 και λουμπρικινη, χρησιμοι στην θεραπευτικη αγωγη οστεοαρθριτιδας και συναφων παθησεων των αρθρωσεων στα θηλαστικα
BR112015022507A2 (pt) ácidos ribonucleicos com nucleotídeos 4'-tio-modificados, composição compreendendo o mesmo e usos relacionados
JO3469B1 (ar) طافرات fgf21 واستخداماتها
EA201001883A1 (ru) Мутанты fgf21 и их применение
BR112012013868A8 (pt) composição, proteína de fusão, polinucleotídeo, vetor ou constructo de gene, célula hospedeira , composição farmacêutica, método in vitro e uso de uma composição.
BR112023020167A2 (pt) Fusões agente-ligante de ligação biespecífica para a degradação de proteínas alvo
EA201990619A1 (ru) Fgf21 мутанты и их применение
BR112012029067A2 (pt) grupos-alvo de receptor do complemento 2 (cr2) melhorados.
MX387164B (es) Proteínas de fusión actriib-fc truncadas.
MY150226A (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and medicinal use
BR112015011697A2 (pt) antibióticos macrocíclicos de amplo espectro
BR112022010882A2 (pt) Oligômeros antissenso para tratamento de condições e doenças
BR112016011091A2 (pt) sequência de endolisina kz144 modificada
MX2018003850A (es) Moleculas de transporte de antigeno modular mejoradas y sus usos en animales.
BRPI0515604A (pt) método para o tratamento de células de cáncer e método de tratamento de uma doença imune relacionada
Tzabazis et al. Antihyperalgesic effect of a recombinant herpes virus encoding antisense for calcitonin gene-related peptide.
BRPI0923854A2 (pt) Métodos para tratar ou prevenir osteoartrite em um animal de estimação e uma condição degenerativa de articulação em um animal de estimação, para modular degradação enzimática de cartilagem articular em um animal de estimação, e para diminuir a liberação de glicosaminoglicano do tecido de cartilagem de um animal de estimação.
BRPI0506689A (pt) composições compreendendo memantina e polìmeros polianiÈnicos para administração ao olho
MX2013007191A (es) Metodos y composiciones para prevenir y tratar la osteoartritis.
BRPI0616936B8 (pt) composição farmacêutica
BR112013002702A2 (pt) vacina
WO2008060568A3 (en) Amide-substituted aryl piperidines
LONG et al. Effects of active immunization against myostatin on carcass quality and expression of the myostatin gene in pigs

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DA PRIORIDADE US 11/867,919 DE 05/10/2007 REIVINDICADA NO PCT/US2008/079090, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O, DECRETO NO. 635 DE 21/08/1992 E CONVENCAO DA UNIAO DE PARIS (REVISTA EM ESTOCOLMO 14/07/1967), ART. 4O, ALINEA C, ITEM 1. ESTA PERDA SE DEU PELO FATO DO BRASIL NAO ACEITAR RESTAURACAO DE PRIORIDADE (RESERVA DO BRASIL DE ACORDO COM A REGRA 49TER.1 ALINEA (G) E 49TER.2 ALINEA (H) DO REGULAMENTO DE EXECUCAO DO PCT), RESTAURACAO ESTA QUE FOI CONCEDIDA PELA OMPI, JA QUE O PRAZO PARA O DEPOSITO INTERNACIONAL COM REIVINDICACAO DE PRIORIDADE ULTRAPASSOU OS 12 MESES.

B25C Requirement related to requested transfer of rights

Owner name: MERIAL LIMITED (GB)

B25A Requested transfer of rights approved

Owner name: MERIAL, INC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL